Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis

Inclusion criteria

• Diagnosis of RRMS according to the revised McDonald criteria (2017 or 2024 revisions).
• Initiation of ocrelizumab s.c in accordance with routine clinical practice and local prescribing information.
• The decision to initiate ocrelizumab s.c. has been made by the treating physician prior to and independently of study participation.
• Willingness to complete the patient-reported outcome questionnaire TASQ, where applicable.

Exclusion criteria

• Participation in any clinical study involving disease modifying therapies for multiple sclerosis during the study period or at the time of enrollment.
• Prior treatment with rituximab.
• Contraindications to ocrelizumab as per the local prescribing information.
• Severe psychiatric or cognitive impairment that, in the opinion of the treating physician, would preclude informed consent, reliable participation in the study, or completion of patient-reported outcomes.
• Any condition which, in the opinion of the treating physician, would interfere with participation in the study or the interpretation of study results.
• For participants participating in a Market Research and Patient Support Program (MAP), inclusion is permitted only when a cross-reference to the unique MAP patient identifier is available.